ReviewBiomolecules2026
Polycomb Repressive Complex 2 (PRC2): A Context-Dependent Epigenetic Regulator of Brain Aging.
Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain aging is characterized by extensive and dynamic epigenetic changes that reshape chromatin architecture and influence gene regulatory networks, leading to deregulation of transcriptional programs essential for neuronal survival, synaptic plasticity, and cognitive function. Emerging studies highlight the pivotal regulatory role of the Polycomb Repressive Complex 2 (PRC2) in brain aging, functioning mainly as an epigenetic silencer through the establishment of the H3K27me3 histone mark at gene promoters and enhancers, leading to transcriptional repression. Altered distribution and decreased activity of PRC2 during aging disrupts the balance between gene activation and repression, affecting pathways involved in neurogenesis, synaptic plasticity and stress response. Further interplay with other epigenetic regulators such as histone deacetylase 2 (HDAC2), DNA methyltransferases and non-coding RNAs forms an extensive network that contributes to cognitive decline, increasing vulnerability for neurodegeneration. In this review, we describe structural and functional aspects of PRC2, with emphasis on the potential of this epigenetic context-dependent regulator to integrate developmental, environmental and aging-related signals, to shape the transcriptional landscape of aging brain. We also discuss the newly developed PRC2-AgeIndex, which serves as a prognostic biomarker for age-related neurodegeneration and monitoring treatment response, as well as current PRC2-targeting options for healthy brain aging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.